Our study highlights a novel role of Chi3L1 in promoting fibrosis in SSc, and our findings suggest the potential anti‐fibrotic capability and clinical applicability of IL‐17RA antagonists in patients with SSc. This evidence concerns the gene CHI3L1 and systemic sclerosis.